-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

SVB Leerink Maintains Outperform on Century Therapeutics, Lowers Price Target to $14

Benzinga · 01/06/2023 07:25
SVB Leerink analyst Daina Graybosch maintains Century Therapeutics (NASDAQ:IPSC) with a Outperform and lowers the price target from $20 to $14.